TY  - GEN
AB  - Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the most common form of neuroendocrine neoplasia, but there is no current consensus for the sequencing of approved therapies, particularly with respect to peptide receptor radionuclide therapy (PRRT). Surgical resection is recognized as the only clinically curative measure for GEP-NETs; however, given that these tumors have a propensity to metastasize and the primary tumor may, in some cases, be unresectable, various treatment options have been introduced including PRRT. This review evaluates the data supporting approved therapies for GEP-NETs and the current recommendations for therapeutic sequencing with a focus on PRRT and how sequencing might change with respect to the increasing body of literature regarding PRRT utilization.
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AU  - Raymond, Lauren M.
AU  - Korzun, Tetiana
AU  - Kardosh, Adel
AU  - Kolbeck, Kenneth J.
AU  - Pommier, Rodney F.
AU  - Mittra, Erik S.
DA  - 2021
DO  - 10.6083/ws859g38c
DO  - DOI
ID  - 9243
KW  - Neuroendocrine Tumors
KW  - Receptors, Peptide
KW  - gastroenteropancreatic neuroendocrine tumor
KW  - (177lutetium-dota(o)tyr3)octreotate
L1  - https://digitalcollections.ohsu.edu/record/9243/files/Raymond-Lauren-OHSU-ResearchWeek-2021.pdf
L2  - https://digitalcollections.ohsu.edu/record/9243/files/Raymond-Lauren-OHSU-ResearchWeek-2021.pdf
L4  - https://digitalcollections.ohsu.edu/record/9243/files/Raymond-Lauren-OHSU-ResearchWeek-2021.pdf
LA  - eng
LK  - https://digitalcollections.ohsu.edu/record/9243/files/Raymond-Lauren-OHSU-ResearchWeek-2021.pdf
N2  - Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the most common form of neuroendocrine neoplasia, but there is no current consensus for the sequencing of approved therapies, particularly with respect to peptide receptor radionuclide therapy (PRRT). Surgical resection is recognized as the only clinically curative measure for GEP-NETs; however, given that these tumors have a propensity to metastasize and the primary tumor may, in some cases, be unresectable, various treatment options have been introduced including PRRT. This review evaluates the data supporting approved therapies for GEP-NETs and the current recommendations for therapeutic sequencing with a focus on PRRT and how sequencing might change with respect to the increasing body of literature regarding PRRT utilization.
PB  - Oregon Health and Science University
PY  - 2021
T1  - A comprehensive review of the therapeutic options for gastroenteropancreatic neuroendocrine tumors with a focus on PRRT and its sequencing
TI  - A comprehensive review of the therapeutic options for gastroenteropancreatic neuroendocrine tumors with a focus on PRRT and its sequencing
UR  - https://digitalcollections.ohsu.edu/record/9243/files/Raymond-Lauren-OHSU-ResearchWeek-2021.pdf
Y1  - 2021
ER  -